Heavy Silicone Oil as a Long-Term Endotamponade Agent for Complicated Retinal Detachments

Table 3

Comparison between LogMAR BCVA at baseline, month 1, month 6, and final in patients in whom HSO was removed and patients in whom HSO was not removed.

	Baseline	Month 1	Month 6	Final
HSO not removed (𝑛=14)
Mean	1.90	1.22	1.07	1.03
SD	0.58	0.58	0.63	0.66
Median	1.79	1.15	0.80	0.80
Min	1.00	0.60	0.49	0.20
Max	2.70	2.20	2.20	2.20
HSO removed (𝑛=11)
Mean	1.87	1.33	1.24	1.11
SD	0.63	0.74	0.80	0.79
Median	2.20	1.00	1.00	1.00
Min	1.00	0.30	0.20	0.09
Max	2.70	2.20	2.20	2.20

Patients in whom HSO was not removed.
Baseline > month 1 (𝑃=0.001), month 6 (𝑃=0.001), and final (𝑃=0.001).
Month 1 > month 6 (𝑃=0.027), final (𝑃=0.027).
Month 6 = final (𝑃=0.180).
Patients in whom HSO was removed.
Baseline > month 1 (𝑃=0.008), month 6 (𝑃=0.008), and final (𝑃=0.005).
Month 1 = month 6 (𝑃=0.068); month 1> final (𝑃=0.028).
Month 6 = final (𝑃=0.068).